Katharine E Harding1, Mark Wardle2, Perry Moore3, Valentina Tomassini1, Trevor Pickersgill2, Yoav Ben-Shlomo4, Neil P Robertson1. 1. Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Cardiff, UK Department of Neurology, Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Cardiff, UK. 2. Department of Neurology, Helen Durham Centre for Neuroinflammatory Disease, University Hospital of Wales, Cardiff, UK. 3. Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Cardiff, UK Department of Neuropsychology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK. 4. School of Social and Community Medicine, Bristol, UK.
Abstract
BACKGROUND: A minority of patients with multiple sclerosis (MS) have primary progressive disease (PPMS). Treatment options are currently limited, but as prospects for interventional studies become more realistic, understanding contemporary outcome data will be key to successful trial design. METHODS: 234 PPMS patients were identified from a population-based cohort of 2131 (11.0%) and mean follow-up of 13.1 years. Time to established disability endpoints was compared with patients with relapsing-onset MS (ROMS) using survival analysis, and Cox regression employed to explore factors contributing to disability accumulation. Results were used to create predictive power models for clinical trials in PPMS. RESULTS: Time to fixed disability milestones was shorter than in ROMS (Expanded Disability Status Scale (EDSS) 4.0:8.1 vs. 17.1 years, p<0.001; EDSS 6.0: 9.6 vs. 22.1 years, p<0.001; EDSS 8.0: 20.7 vs. 39.7 years, p<0.001), but there were no differences in age-related disability. Age and cerebellar symptoms at onset affected rate of progression. Modelling of these data indicated that trials employing EDSS change of 1.0 as the primary outcome measure would be powered to detect a 20% difference in progression using 600 patients with initial EDSS of 4.0 per trial arm, or 400 patients with initial EDSS of 5.0 per arm. However, trials including patients with fixed EDSS of ≥6.0 will be underpowered even with large numbers or prolonged duration. CONCLUSIONS: Disability progression in PPMS is variable and influenced by age at onset. Although progression is more rapid, age-related disability milestones are identical to relapsing-onset disease. These data offer a contemporary paradigm for clinical trial design in progressive MS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: A minority of patients with multiple sclerosis (MS) have primary progressive disease (PPMS). Treatment options are currently limited, but as prospects for interventional studies become more realistic, understanding contemporary outcome data will be key to successful trial design. METHODS: 234 PPMS patients were identified from a population-based cohort of 2131 (11.0%) and mean follow-up of 13.1 years. Time to established disability endpoints was compared with patients with relapsing-onset MS (ROMS) using survival analysis, and Cox regression employed to explore factors contributing to disability accumulation. Results were used to create predictive power models for clinical trials in PPMS. RESULTS: Time to fixed disability milestones was shorter than in ROMS (Expanded Disability Status Scale (EDSS) 4.0:8.1 vs. 17.1 years, p<0.001; EDSS 6.0: 9.6 vs. 22.1 years, p<0.001; EDSS 8.0: 20.7 vs. 39.7 years, p<0.001), but there were no differences in age-related disability. Age and cerebellar symptoms at onset affected rate of progression. Modelling of these data indicated that trials employing EDSS change of 1.0 as the primary outcome measure would be powered to detect a 20% difference in progression using 600 patients with initial EDSS of 4.0 per trial arm, or 400 patients with initial EDSS of 5.0 per arm. However, trials including patients with fixed EDSS of ≥6.0 will be underpowered even with large numbers or prolonged duration. CONCLUSIONS: Disability progression in PPMS is variable and influenced by age at onset. Although progression is more rapid, age-related disability milestones are identical to relapsing-onset disease. These data offer a contemporary paradigm for clinical trial design in progressive MS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Lauren B Zapata; Titilope Oduyebo; Maura K Whiteman; Maria K Houtchens; Polly A Marchbanks; Kathryn M Curtis Journal: Contraception Date: 2016-07-21 Impact factor: 3.375
Authors: Guoqiao Wang; Gary R Cutter; Stacey S Cofield; Fred Lublin; Jerry S Wolinsky; Tarah Gustafson; Stephen Krieger; Amber Salter Journal: Mult Scler Date: 2016-09-28 Impact factor: 6.312
Authors: Jordana Hughes; Vilija Jokubaitis; Alessandra Lugaresi; Raymond Hupperts; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Francois Grand'Maison; Pierre Grammond; Patrizia Sola; Diana Ferraro; Cristina Ramo-Tello; Maria Trojano; Mark Slee; Vahid Shaygannejad; Cavit Boz; Jeanette Lechner-Scott; Vincent Van Pesch; Eugenio Pucci; Claudio Solaro; Freek Verheul; Murat Terzi; Franco Granella; Daniele Spitaleri; Raed Alroughani; Jae-Kwan Jun; Adam Fambiatos; Anneke Van der Walt; Helmut Butzkueven; Tomas Kalincik Journal: JAMA Neurol Date: 2018-11-01 Impact factor: 18.302
Authors: Julie Latchem-Hastings; Elizabeth Randell; Kate Button; Fiona Jones; Rachel Lowe; Helen Dawes; Fiona Wood; Freya Davies; Vincent Poile; Rhian O'Halloran; Barbara Stensland; Emma Tallantyre; Rebecca Playle; Adrian Edwards; Monica Busse Journal: Pilot Feasibility Stud Date: 2021-05-22
Authors: Karen Ann Ribbons; Patrick McElduff; Cavit Boz; Maria Trojano; Guillermo Izquierdo; Pierre Duquette; Marc Girard; Francois Grand'Maison; Raymond Hupperts; Pierre Grammond; Celia Oreja-Guevara; Thor Petersen; Roberto Bergamaschi; Giorgio Giuliani; Michael Barnett; Vincent van Pesch; Maria-Pia Amato; Gerardo Iuliano; Marcela Fiol; Mark Slee; Freek Verheul; Edgardo Cristiano; Ricardo Fernandez-Bolanos; Maria-Laura Saladino; Maria Edite Rio; Jose Cabrera-Gomez; Helmut Butzkueven; Erik van Munster; Leontien Den Braber-Moerland; Daniele La Spitaleri; Alessandra Lugaresi; Vahid Shaygannejad; Orla Gray; Norma Deri; Raed Alroughani; Jeannette Lechner-Scott Journal: PLoS One Date: 2015-06-05 Impact factor: 3.240
Authors: T Ziemssen; S Rauer; C Stadelmann; T Henze; J Koehler; I-K Penner; M Lang; D Poehlau; M Baier-Ebert; H Schieb; S Meuth Journal: PLoS One Date: 2015-09-22 Impact factor: 3.240